Bluejay Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
/EIN News/ -- REDWOOD CITY, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company rapidly progressing transformative therapies for viral hepatitis and other serious liver diseases, today announced that company Founder and Chief Executive Officer Keting Chu, M.D., Ph.D., will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis San Francisco on Monday, January 13, 2025, at 3 p.m. PST. Dr. Chu and her leadership team will also participate in one-on-one investor meetings at the conference.
About Bluejay Therapeutics
Bluejay Therapeutics is a clinical-stage biopharmaceutical company focused on the development of potentially life-changing treatments for viral hepatitis and liver diseases. The company is currently investigating brelovitug (BJT-778) for the treatment of chronic hepatitis D and chronic hepatitis B. Additionally, Bluejay is advancing several innovative programs with the goal of developing a combination regimen to achieve a functional cure for chronic hepatitis B, including a proprietary TLR9 agonist (cavrotolimod) and a liver-targeted hepatitis B virus (HBV) transcript inhibitor (BJT-628). For more information on Bluejay Therapeutics, please visit the company’s website at www.bluejaytx.com or follow the company on LinkedIn.
Media Contact:
Dan Boyle
Orangefiery
media@orangefiery.com
818-209-1692
Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release